Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
Status:
Terminated
Trial end date:
2017-03-15
Target enrollment:
Participant gender:
Summary
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib
(Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC)
patients with platelet counts 100,000/µL. The purpose of this study is to determine the tumor
control rate following treatment with GEM-OX combined with Tarceva in patients with HCC.
Tumor control rate is defined as the percentage of patients achieving a complete response,
partial response, or stable disease at 24 weeks following treatment.